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Analysis of Six Candidate Genes as Potential Modifiers of Disease
Expression in Canine XLPRA1, a Model for Human X-Linked Retinitis
Pigmentosa 3
Abstract
Purpose: Canine X-linked progressive retinal atrophy (XLPRA) is caused by mutations in RPGR exon
ORF15, which is also a mutation hotspot in human X-linked retinitis pigmentosa 3 (RP3). The XLPRA1 form
of disease has shown extensive phenotypic variability in a colony of dogs that all inherited the same mutant X-
chromosome. This variability in onset and severity makes XLPRA1 a valuable model to use to identify genes
influencing photoreceptors degeneration in dog and to elucidate molecular mechanisms underlying RP in its
human homolog. In this study, RPGRIP1, RANBP2, NPM1, PDE6D, NPHP5, and ABCA4 genes were
selected on the basis of interaction with RPGR or RPGRIP1 or their implication in related retinal diseases,
and were investigated as candidate genetic modifiers of XLPRA1.
Methods: A pedigree derived from an affected male dog outcrossed to unrelated normal mix bred or purebred
females was used. Morphologic examination revealed phenotypic variability in the affected dogs characterized
as mild, moderate, or severe. Single nucleotide polymorphisms (SNPs) and indel-containing markers
spanning the entire genes were designed, based on the canine sequence and the Broad Institute SNP library,
and genotyped on the pedigree. For each candidate gene, haplotypes were identified and their frequencies in
severely and moderately affected dogs were compared to detect a putative correlation between a gene-specific
haplotype(s), and severity level of the disease. Primers were derived from expressed sequence tags (ESTs) and
predicted transcripts to assess the relative retinal expression of the six genes of interest in normal and affected
retinas of different ages.
Results: Four to seven haplotypes per gene were identified. None of the haplotypes of RPGRIP1, NPM1,
PDE6D, NPHP5, RANBP2, and ABCA4 were found to co-segregate with the moderate or severe phenotype.
No significant difference in the retinal expression levels of the candidate genes was observed between normal
and affected dogs.
Conclusions: The haplotype distribution of RPGRIP1, NPM1, PDE6D, NPHP5, RANBP2, and ABCA4
suggests these genes are not modifiers of the disease phenotype observed in the XLPRA1 pedigree. The
RPGRORF15 stop mutation does not affect the retinal expression of these genes at the mRNA level in the pre-
degenerate stage of disease, but no conclusions can be made at this time about changes that may occur at the
protein level.
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 The X-linked retinitis pigmentosa form 3 (RP3), one of
the most severe forms of retinitis pigmentosa (RP), is charac-
terized by early onset of central vision loss and night blind-
ness, constriction of visual fields, and complete blindness in
young adults [1-5]. Although several genes and genetic loci
have been implicated in XLRP, by far the largest proportion
of cases results from mutations in the RP GTPase regulator
gene (RPGR), particularly in the recently characterized exon
ORF15 [6,7]. RPGR mutations account for about 8-10% of
RP cases in North America, and 15-20% in Europe [5,8,9]; of
RP simplex patients, about 25% have RPGR mutations
[2,5,10]. Experimentally produced and naturally occurring
models of RPGR-XLRP have been described, respectively, for
the mouse and dog. In mice, a knockout (KO), resulting from
an in-frame deletion of exons 4-6, and a gain of function mu-
tant produced by a truncation of ORF15 have been reported
[11,12]. The KO mouse shows normal development and slow
degeneration [11], while the gain of function mutant shows
early-onset degeneration after abnormal photoreceptor devel-
opment [12]. In the dog, two microdeletion mutations in exon
ORF15 have been identified; a premature stop (XLPRA1) in
the Siberian husky and Samoyed breeds, and a frame-shift
mutation (XLPRA2) in mixed-breed dogs [13]. The dog is the
only naturally occurring model of RPGR-XLRP.
In XLPRA1, a five nucleotide deletion (del1028-1032) in
exon ORF15 causes an immediate premature stop codon that
will result in a protein truncated of its 230 C- terminal amino
acids. Morphological characterization showed that photore-
ceptor cells develop and function normally, but then undergo
a progressive degeneration of rods and cones. Using morpho-
logic criteria, rods are affected first, while cone degeneration
and cell death are later events [13,14]. Because there is nor-
mal retinal development before degeneration ensues, the dis-
ease is similar to the KO mouse [11], although the degenera-
tion rate comparably is faster. This would suggest that the
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Purpose: Canine X-linked progressive retinal atrophy (XLPRA) is caused by mutations in RPGR exon ORF15, which is
also a mutation hotspot in human X-linked retinitis pigmentosa 3 (RP3). The XLPRA1 form of disease has shown exten-
sive phenotypic variability in a colony of dogs that all inherited the same mutant X-chromosome. This variability in onset
and severity makes XLPRA1 a valuable model to use to identify genes influencing photoreceptors degeneration in dog
and to elucidate molecular mechanisms underlying RP in its human homolog. In this study, RPGRIP1, RANBP2, NPM1,
PDE6D, NPHP5, and ABCA4 genes were selected on the basis of interaction with RPGR or RPGRIP1 or their implication
in related retinal diseases, and were investigated as candidate genetic modifiers of XLPRA1.
Methods: A pedigree derived from an affected male dog outcrossed to unrelated normal mix bred or purebred females
was used. Morphologic examination revealed phenotypic variability in the affected dogs characterized as mild, moderate,
or severe. Single nucleotide polymorphisms (SNPs) and indel-containing markers spanning the entire genes were de-
signed, based on the canine sequence and the Broad Institute SNP library, and genotyped on the pedigree. For each
candidate gene, haplotypes were identified and their frequencies in severely and moderately affected dogs were compared
to detect a putative correlation between a gene-specific haplotype(s), and severity level of the disease. Primers were
derived from expressed sequence tags (ESTs) and predicted transcripts to assess the relative retinal expression of the six
genes of interest in normal and affected retinas of different ages.
Results: Four to seven haplotypes per gene were identified. None of the haplotypes of RPGRIP1, NPM1, PDE6D, NPHP5,
RANBP2, and ABCA4 were found to co-segregate with the moderate or severe phenotype. No significant difference in the
retinal expression levels of the candidate genes was observed between normal and affected dogs.
Conclusions: The haplotype distribution of RPGRIP1, NPM1, PDE6D, NPHP5, RANBP2, and ABCA4 suggests these
genes are not modifiers of the disease phenotype observed in the XLPRA1 pedigree. The RPGRORF15 stop mutation
does not affect the retinal expression of these genes at the mRNA level in the pre-degenerate stage of disease, but no
conclusions can be made at this time about changes that may occur at the protein level.
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RPGR function is not essential for normal retinal develop-
ment, but is required for long-term photoreceptor maintenance
and viability.
The pedigree developed to characterize the genetics of
the then unknown retinal degeneration locus responsible for
XLPRA1, and used to map/clone the disease gene, was con-
structed from a single affected male outcrossed to unrelated
normal females of other breeds that were part of the research
colony [14,15]. Even though all affected dogs inherited the
single mutant X-chromosome and a stable disease-causing
microdeletion, we found that affected males showed variabil-
ity in onset and severity of the retinal disease phenotype, and
these were characterized as mild, moderate, or severe [14].
Due to the breeding strategy used to develop the pedigree, all
the affected progeny received the same RPGR mutant allele,
thus excluding heterogeneity at the primary locus [15]. Envi-
ronmental factors also were excluded as all dogs were raised
in the same environment in a dedicated research colony facil-
ity where they received the same diet, medical care, and light
exposure. The phenotypic variability observed in XLPRA1,
therefore, results from the genetic background, i.e., second-
ary modifier genes(s), influencing the phenotype. The
XLPRA1 dog model represents a valuable resource for the
identification of those disease modifier genes that influences
the course of RPGR-associated photoreceptor degeneration.
These modifier genes may lead to the identification of new
molecular mechanisms likely to elucidate phenotype variabil-
ity among human RP3, and possibly among and between other
forms of RP.
The means by which mutations in secondary genes influ-
ence the effect of a primary mutation has been reviewed [16-
18]. Examples include CYP1B1, which has been identified as
a severity modifier that potentially influences the age of onset
of dominant glaucoma caused by MYOC mutations [19]. Simi-
larly, the tyrosinase gene has been shown to act as a modifier
in glaucoma in the CYP1B1 KO mouse model [20]. Molecu-
lar mechanisms can also rely on interaction of proteins be-
longing to the same complexes, as exemplified in digenic in-
heritance in RP caused by concomitant mutations in RDS and
ROM1 genes [21].
In this initial screening, we investigated five candidate
modifier genes selected on the basis of direct or indirect pro-
tein interaction with RPGR or RPGRIP1. These two proteins
have been localized to the connecting cilia/proximal outer seg-
ment in mice and other mammalian species [22-26]. These
genes included RPGRIP1, PDE6D, RANBP2, NPM1, and
NPH5; as a control, ABCA4 also was evaluated. We tested the
simplest hypothesis that any one of these genes acted as a
single locus modifier, and determined if the phenotypic vari-
ability could be explained by the presence or absence of a
specific allele of the gene in homozygous/heterozygous state
in dogs divided into different phenotype severity categories.
The association between gene, i.e., a specific segregating hap-
lotype, and phenotype was only used as an indicator, but the
responsible sequence change could not be inferred if a corre-
lation existed. As the population at our disposal was too small
to undertake a linkage analysis, we compared haplotype fre-
quencies in these two phenotype categories. We found no cor-
relation between the degree of disease severity and the candi-
date genes tested. In parallel, the retinal RNA expression of
the candidate genes was evaluated in normal and pre-degen-
erate mutant retinas. No disease-specific changes in expres-
sion were found.
METHODS
Pedigree resources and disease assessment:  Origin and com-
position of the study colony. All dogs were bred and main-
tained at the Retinal Disease Studies Facility (RDSF), Uni-
versity of Pennsylvania, New Bolton Center, Kennett Square,
PA. These dogs are maintained under specific and standard
conditions where all animals have the same exposure to cy-
clic light (12 h on/12 h off), receive the same diet, and have
the same medical procedures and vaccinations. For tissue col-
lection and expression studies, the dogs were anesthetized by
intravenous injection of sodium pentobarbital, enucleated, and
then euthanized. All procedures involving animals were done
in compliance with the ARVO Statement for the Use of Ani-
mals in Ophthalmic and Vision Research.
The colony was established by outcrossing one XLPRA1
affected male Siberian husky to unrelated normal female
beagles known to be free from inherited retinal degeneration.
The carrier and affected progeny was subsequently mated with
mixed breed or purebred dogs of varied genetic background,
resulting in the creation of a highly polymorphic and informa-
tive pedigree [15]. As the initial goal of the project was to
produce a sufficient number of informative dogs to fine map
the retinal disease, dogs were selected for breeding whose dis-
ease phenotype could be readily identified before 1 year of
age, or if carrier females were used, would produce more males
whose disease status was severe and ascertainment was pos-
sible at an early age.
Determination of the phenotypic status:  A subset of this
colony, consisting of 43 dogs, was selected for the studies (Fig-
ure 1); the group included the founder, and some of his de-
scendants. Dogs were included based on the results of serial
clinical assessment of retinal disease status using indirect oph-
thalmoscopy and electroretinography (ERG). Methods for
these procedures have been previously described [13,15].
These methods were considered complementary to the main
assessment criterion, which was morphologic evaluation us-
ing high resolution optical microscopy of 1 µm plastic sec-
tions of retinas fixed in paraformaldehyde-glutaraldehyde-os-
mium tetroxide [27]. Assessment was made with examiner
masked as to the genotype (affected, carrier ,and normal), and
genotype status of all study dogs was confirmed using a pre-
viously described molecular diagnostic test [13]. Included in
the study were 22 hemizygous males and 2 homozygous fe-
males (Figure 1). The disease characteristics and metrics in
both are the same [13,14].
Morphologic criteria were used to establish grades of dis-
ease severity taking into account the animal’s age, and degree
and extent of disease [14]. There were three grades: (1) mild
(degeneration present only in periphery after 1.5 years of age
or later), (2) moderate (peripheral retinal degeneration devel-
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Figure 1. Pedigree of XLPRA1 affected dogs.  H2 is a purebred Siberian husky founder that was outcrossed to dogs from various breeds.
Those dog breeds contributing to the pedigree include Irish setter, Alaskan malamute, miniature schnauzer, and poodle. Severely affected dogs
are in black, moderately affected dogs in dark grey, and mildly affected dogs in crosshatch pattern. Squares represent male and circles
represent female. All affected males are hemizygous; affected females H59 and H64 are homozygous for the mutation. Dotted circles are
carrier females that were not included in the phenotype analysis. The following abbreviations were used: (B) purebred beagle, (N) mixed breed
control, and (E) Norwegian elkhound-derived outcross.
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ops between 11 and 15 months of age), and (3) severe (photo-
receptor degeneration-Stage 2 or more advanced-present both
centrally and peripherally) [14]. Of the 24 affected dogs in
this subset pedigree, 14 were classified as severe, nine as
moderate, and one as mild; In the disease-association studies,
only those with moderate and severe disease were used for
analysis.
Sample collection and DNA/RNA extraction:  Genomic
DNA was isolated from citrated blood or spleen samples ei-
ther by a standard phenol-chloroform based protocol or by
using the QIAamp DNA kit (Qiagen, Valencia, CA) and fol-
lowing the manufacturer’s directions. Retinas were collected
within 1 min after enucleation under sterile and RNase-free
conditions, frozen by immersion in liquid nitrogen, and stored
at -70 °C until utilized. Collection of retinal samples was done
in the morning to avoid the variations in retinal RNA expres-
sion with light:dark cycles [28]. RNA was isolated from retina
using a standard guanidinium isothiocyanate-based protocol.
For the expression studies, we used 8 affected and 3 controls
dogs ranging 8-67 weeks.
Selection of candidate genes and haplotype identification:
Candidate genes: Six genes were chosen for analysis, five of
which interact directly or indirectly with RPGR. RPGRIP1
interacts with the N-terminal RCC1-homologous domain of
RPGR [25,29]. NPM1 codes for the chaperone protein that
interacts with the C-terminal C2 domain of RPGR [30], NPHP5
is complexed with RPGR and localizes to connecting cilia of
photoreceptors [31]. PDE6D interacts with the RCC1-homolo-
gous domain of RPGR, and is attached at the disk membranes
of rod outer segments [32]. Alternatively, RANBP2 associ-
ates with RPGRIP1, and possibly mediates its nucleocytoplas-
mic shuttling [33]. Though the roles of these proteins in the
RPGR complex are not fully understood, numerous mutations
have been described leading to retinal degenerations, e.g.,
Leber congenital amaurosis in the case of RPGRIP1 [34,35],
or Senior-Loken syndrome in the case of NPHP5 [31]. We
selected ABCA4 as a control gene because of its ubiquitous
involvement in other retinal diseases, including Stargardt
macular degeneration and RP [36,37].
Marker selection:  Candidate genes were investigated us-
ing a fine-scale single nucleotide polymorphism (SNP) analysis
[38]. Markers were selected from upstream, downstream, and
intronic regions of the genes of interest in an effort to obtain
regularly spaced polymorphic markers spanning the entire
gene. Polymorphic sites consisting of SNPs and insertion/de-
letions (indels) were identified in markers designed either based
on the Broad Institute SNP database (Broad), or from ran-
domly selected regions picked from the canine sequence (Ge-
nome). Markers of length ranging from 300 bp to 1500 bp
were designed using Primer3 software (Primer3) using default
primers picking conditions (20 bp optimum size, 60 °C opti-
mum Tm). Markers were first genotyped in a subset of the
pedigree comprising the most outbred animals in order to check
their polymorphism. A minimal set of markers showing infor-
mative SNPs or indels was genotyped on the whole pedigree
to identify the segregating haplotypes (Table 1). Increasing
marker density did not identify more haplotypes because of
redundant information provided by markers showing similar
pattern of variation.
Genotyping protocol and haplotype construction: PCR
reactions were performed on 50 ng of genomic DNA in a final
volume of 10 µl containing 0.5 U of AmpliTaq Gold (Applied
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TABLE 1. HAPLOTYPING MARKER CHARACTERISTICS AND ASSOCIATED POLYMORPHISM
                                                                 Size
   Name              Primer U                   Primer L         (bp)        Protocol           Polymorphism coordinates (1)      HE (2)
-----------   -----------------------   ----------------------   ----   ------------------   ----------------------------------   ------
RPGRIP-5fd2   ATGGCATGAATGCAGTGAAC      CTGGTGTCCTCTGGTCCTGT     518    sequencing (U)       chr15:21,323,467               C/T   0,27
RPGRIP-og     ATGTCTGTGTGTCTATCAGGTG    GTTTGCAGAACACATGGCATTC   305    digestion (Bsu36i)   21 364 923                     A/G   0,27
RPGRIP-int2   TTGAATGGTGGGCTAGGAAG      ACCCAAGGCCACTTTACTCA     702    sequencing (U)       21 372 856                     A/G   0,43
RPGRIP-3f     GATGAGGTGATGAGGGCCTA      CCGTGGTTAACGTTTGCTTT     1463   digestion (AvaII)    21 434 804                     C/T   0,50
RANBP-3fc     TTGGTGAATGCCAAATGAAA      AGCCTGCTGAATGGTTGAAG     717    sequencing (U)       chr10:38,199,076               C/T   0,47
RANBP-int23   ATGCAACAGATGCAAATCCA      CGTTCCTGCCCTTCAAGTAA     1127   sequencing (U)       38 224 775                     G/T   0,49
RANBP-int17   GTGGAAACATTCTGGGGAGA      GGGCTTTTTGAATGCTGTGT     1146   sequencing (U)       38 238 339                     T/C   0,19
                                                                                             38 238 358                     A/T   0,10
RANBP-int16   TCCCCAATCGCAGAAACTAC      CTCCACCAGGTGTGAATCCT     1197   sequencing (U)       38 242 341                     A/C   0,27
RANBP-5f      TTGACATCTTGGGTCCAGTG      TGAATGGGGAAATGATTGCT     1156   digestion (AgeI)     38 272 947                     G/T   0,39
                                                                        sequencing (L)       38 273 061                     A/G   0,19
NPM-snp7      GGCAGAACCCACCTGTAGAA      TTTCTTCGCCCTCAATGTCT     631    sequencing (U)       chr4:43,891,628                A/G   0,27
NPM-3fb       CAGACCCTTAGGCAGACGAG      TTTTTGCAGGCACTTCCTTT     1182   sequencing (U)       43,947,526-7                 delAA   0,39
NPM-snp3      TTCTTTGAGCCCATGGAAGT      CTGGCACCCCTCCAAAATA      512    sequencing (U)       43,967,091                     C/T   0,49
NPM-5f        GAAATTTGATGGGCAGAGGA      GCCAGGAGCTAGAGGTGATG     1145   digestion (AflIII)   43,971,373-4               insTGTA   0,43
PDE-snp16     TGGTAGGCTGATTTTCTGGTG     CCTGCTTTCCTGGACAAACT     499    sequencing (U)       chr25:46,552,131               A/G   0,27
                                                                                             46 552 193                     C/T   0,19
                                                                                             46 552 331                     C/T   0,10
PDE-snp1      TTTGCATTTCCGAGCTCTTT      ACCAAAACAGGATGGACGAG     511    sequencing (U)       46 577 289                     C/T   0,27
PDE-snp10     TTTGGAAAATCAGACGCAAA      GCTTGATCTCGGGGTTATGA     531    sequencing (U)       46 647 231                     A/G   0,43
NPHP-snp2     GAAATTAACCCAAACTTCAGCAA   TTCCTTGGCTGTGACTTCCT     464    sequencing (U)       chr33:28,099,052               A/G   0,49
                                                                                             28 099 062                     A/C   0,43
NPHP-snp3b    TTGCATCAACACCTCATTGTC     CCCATCGTTTGATATTCAGAAA   427    sequencing (U)       28 126 211                     C/T   0,19
NPHP-snp5b    CTGGCTGATGAGAGGTCTTG      GCTCCTTTTCCTACCTCAACAA   344    sequencing (U)       28 155 878                     A/T   0,49
                                                                                             28 155 919                     G/T   0,19
ABCR-snp6     TTACAGGCCTTCCTCCACAC      GGCCAAAGGAAGACACGATA     700    sequencing (U)       chr6:58,159,994                C/T   0,49
                                                                                             58 160 171                     C/T   0,10
                                                                                             58 160 466                     A/G   0,27
ABCR-snp3     TGGTGTTTGGCTTCTGTGAA      CCTTCGGACATGGTTCAGTT     600    sequencing (U)       58 257 868                     G/T   0,10
                                                                                             58 257 905                     C/T   0,39
Genotypes were assessed by sequencing PCR products using upper (U) or lower (L) primers, or by digestion with the restriction enzyme
indicated in parenthesis. 1. Polymorphism coordinates were based on the version (v2.0) of the canine sequence. 2. Expected heterozygosity
(HE) was calculated from the subset of the ten most outbred animals.
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Biosystems, Foster City, CA) or standard Taq polymerase in
1X of the corresponding reaction buffer, 2 mM MgCl2, 250
µM of each dNTP, and 0.3 µM of each primer. All the reac-
tions were carried out in a PTC-200 thermocycler (MJ Re-
search, Waltham, MA) following a “touch-down” program:
initial denaturation/induction 95°C, followed by 20 cycles of
30 s at 94 °C, 30 s at 63 °C (decreasing by 0.5 °C per cycle), 1
min at 72 °C, and 15 cycles of 30 s at 94 °C, 30 s at 53 °C, 1
min at 72 °C, and a final extension of 2 min at 72 °C. Hybrid-
ization temperatures were lowered by 2 °C when intensity of
the signal was too weak.
PCR products were visualized under ultraviolet light with
EtBr in 1.8% agarose gels. PCR products were either directly
sequenced using upper (U) or lower (L) primer with BigDye
chemistry in an ABI capillary sequencer according to stan-
dard procedures, or digested by an appropriate restriction en-
zyme followed by an electrophoresis on an 8% acrylamide
gel. Genotyping protocols are shown in Table 1. For each gene,
haplotypes were established manually based on the actual and
predicted genotypes at every polymorphic site.
Retinal expression of candidate genes:  For each gene of
interest, cDNA specific probes were made using either the
canine sequence (Genome), dog mRNAs and ESTs when avail-
able, and transcript predictions. Probes ranging from 350 to
600 bp were designed with Primer3 software and default con-
ditions. An Aldolase A (ALDOA) probe of 151 bp was selected
as the internal amplification control [39]. In addition, an op-
sin probe was used as a control for retinal integrity and, to
verify that all samples tested had comparable levels of opsin
expression. Reverse transcription was performed using the
SuperScript first-strand synthesis system (Invitrogen, Carlsbad,
CA) following the manufacturer’s procedure. First-strand
cDNAs were synthesized starting with 5 µg of total RNA from
retina using 50 ng of random hexamer. The cDNAs were puri-
fied using the QIAquick kit (Qiagen). In order to estimate the
relative amount of a cDNA of interest, we adjust PCR condi-
tions specifically to keep amplification still in the exponential
range. PCR reactions were carried out on 20 ng of total cDNA
in a 10 µl reaction mix containing the corresponding cDNA
marker, 0.12 µM of the ALDOA control, 2.5-5 mM MgCl2, 0.5
U of AmpliTaq Gold, 1X of reaction buffer, and 250 µM of
each dNTP. All reactions were carried out according to the
following program: 7 min at 95 °C, followed by 32 cycles of
30 s at 94 °C, 30 s at 63 °C, 1 min at 72 °C and a final exten-
sion of 2 min at 72 °C. Primer sequences and specific condi-
tions are described in Table 2.
PCR products were run on a 1.8% agarose gel containing
EtBr, and digital images acquired (UV light cabinet; Alpha
Innotech Corp., San Leandro, CA). Quantification of the bands
was performed with the Alpha Imager software (v4.0) by scan-
ning the lanes and integrating the peaks, thus expressing the
band intensity in relative absorbance units. The ratio between
the bands corresponding to the cDNA of interest and the inter-
nal control was calculated to normalize for initial variations
in sample concentration, and as a control for reaction effi-
ciency. The ratios were derived from three independent re-
peats of the experiments from which the mean, standard de-
viation and relative standard deviation were calculated.
RESULTS
Polymorphism detection:  To detect polymorphisms within the
pedigree, we picked 19 markers from randomly selected re-
gions of the candidate genes, and 37 markers from the Broad
Institute SNP database, and were able to successfully amplify
and sequence them in the most outbred dogs of the study pedi-
gree. Both types of markers were chosen from non-coding
regions where polymorphism is expected to be the highest.
The randomly selected markers were deliberately chosen for
their large size in order to screen ample regions of the genes.
These markers covered 16.3 kb, and permitted detection of 19
SNPs (1 SNP/850 bp), and 3 indels. Markers based on the
SNPs from the Broad Institute were selected so that they would
surround multiple SNPs in order to maximize the chance of
success. These additional markers covered a total of 20.3 kb,
and contained 76 of these putative SNPs. Of these, a total of
47 SNPs (62%) were truly polymorphic after genotyping of
the most outbred dogs. Differences in SNP frequencies among
the regions investigated were observed; 72% of the putative
SNPs in PDE6D were polymorphic in the pedigree, but only
40% in NPM1. This prompted us to design more markers in
regions seemingly less polymorphic. These markers allowed
the identification of 16 new SNPs not present in the Broad
Institute database, and 8 indels.
Based on their patterns of variation, 21 polymorphic mark-
ers designed using both approaches were retained as they make
up a minimal set for distinction of haplotypes in the genes of
interest. Altogether, these markers spanned 15.9 kb, and in-
cluded 28 SNPs, and 2 indels (see Table 1). For each poly-
morphic site, expected heterozygosity (HE) was calculated from
frequencies of alleles observed in the most outbred animals.
Though these values do not reflect the true heterozygosity in
the whole population, it was a good estimate of the genetic
variability in the pedigree brought by the various contributing
breeds. The HE of the polymorphic sites we investigated ranged
from 0.10 to 0.50 (Table 1).
Haplotyping:  Two to five markers/gene were selected,
and these represented a total of 4-7 polymorphic sites/gene.
They delineated genomic regions ranging from 57 kb for
NPHP5 to 111 kb for RPGRIP1. The genotyping of these
markers allowed the identification of four to seven haplotypes/
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TABLE 2. SEMIQUANTITATIVE POLYMERASE CHAIN REACTION MARKER
CHARACTERISTICS AND SPECIFIC CONDITIONS
                                                                     Primers     MgCl
2
                                                             Size      conc.     conc.
   Name            Primer U                 Primer L         (bp)      (µM)      (mM)
----------   ----------------------   --------------------   ----   ----------   -----
RPGRIP-rg2   CTGAAGCCAGTGAAGCACAA     TCCACGAGGTCTCCTGATTC   610    0,12         3,5
RANBP-rg2    TTCGAAACAGCTGTCAAGAAAC   CAGGTTTGTCCACAGTTCCA   421    0,12         3,5
NPM-rg1      CAACACATTCTTGGCAATGG     CAGCCAAAAATGCACAAAAA   435    0,12         5
PDE6D-rg1    GGGATGCTGAGACAGGAAAG     CCCAAAACCCAAATTCTTGA   426    0,12         5
NPHP-rg1.2   AGGCCATCTCTCACGGAATA     CTTTCCCTTCTGCCTCCTTC   365    0,6          3
ABCR-rg2     CCATGCTAAGGAAGCTGCTC     GTGGTGTCCCCAGTAAGCAT   490    0,12         2,5
RHO-rg2      CTGTGGTCTTTGGTGGTCCT     AGCAGATCAGGAAAGCGATG   421    0,04         2,5
ALDO-rg3     ATCCTGGCTGCAGATGAGTC     ATAGGATGaCACCCCCAATG   151    0,12         2.5-5
Markers designed from the six genes of interest were amplified to-
gether with aldolase gene marker (ALDO) as a control using the in-
dicated conditions. The opsin gene marker (RHO) was amplified in
the same manner in order to estimate the retinal integrity. U indicates
upper primer; L indicates lower primer.
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gene in the normal dogs. The haplotypes of the six genes are
presented in Table 3. The genotypes of the dogs are shown in
Table 4. The frequencies of the haplotypes of the six genes of
interest in affected dogs are presented in Figure 2. The num-
ber of haplotypes identified is obviously related to the num-
ber of polymorphic sites that define them. The distribution
and frequency of these haplotypes in the affected dogs are
also consequent to the high level of inbreeding inside the pedi-
gree. In nonaffected dogs, the highest haplotype frequency of
about 50% was observed in PDE6D and NPHP5, while the
highest haplotype frequency in RANBP2 was only 26%. Four
out of the seven haplotypes in NPM1, RANBP2, and ABCA4
©2007 Molecular VisionMolecular Vision 2007; 13:1094-105 <http://www.molvis.org/molvis/v13/a119/>
TABLE 3. HAPLOTYPES OF THE SIX GENES OF INTEREST TESTED IN THE
XLPRA1 PEDIGREE
RPGRIP1 haplotype   1   2   3   4   5
-----------------   -   -   -   -   -
chr15:21,323,467    C   T   T   C   C
21,364,923          G   G   G   G   A
21,372,856          A   G   G   A   G
21,434,804          C   C   T   T   T
RANBP2 haplotype    1   2   3   4   5   6   7
-----------------   -   -   -   -   -   -   -
chr10:38,199,076    T   T   C   T   C   T   T
38,224,775          T   G   T   G   G   T   T
38,238,339          T   T   C   T   T   T   T
38,238,358          A   T   A   A   A   A   A
38,242,341          A   A   A   A   A   C   A
38,272,947          G   G   G   G   G   T   T
38,273,061          G   G   A   G   G   G   G
NPM1 haplotype      1   2   3   4   5   6   7
-----------------   -   -   -   -   -   -   -
chr4:43,891,628     A   G   A   A   A   G   A
43,947,526-7        -   -   +   -   -   -   +
43,967,091          T   T   C   C   T   T   C
43,971,373-4        +   +   -   +   -   -   +
PDE6D haplotype     1   2   3   4   5
-----------------   -   -   -   -   -
chr25:46,552,131    A   A   A   G   G
46,552,193          C   C   C   C   T
46,552,331          C   C   C   T   C
46,577,289          C   C   T   C   C
46,647,231          G   A   G   A   A
NPHP5 haplotype     1   2   3   4
-----------------   -   -   -   -
chr33:28,099,052    A   A   G   G
28,099,062          A   A   A   C
28,126,211          T   T   C   T
28,155,878          T   A   A   T
28,155,919          G   T   T   T
ABCA4 haplotype     1   2   3   4   5   6   7
-----------------   -   -   -   -   -   -   -
chr6:58,159,994     T   T   C   C   C   C   C
58,160,171          T   T   T   C   T   T   T
58,160,466          G   G   G   G   G   A   G
58,257,868          G   G   G   G   T   G   G
58,257,905          T   C   T   T   T   T   C
Polymorphism coordinates were based on the May 2005 version (v2.0)
of the canine sequence. Haplotypes are presented in columns and are
numbered from one to seven.
occurred in 10% or less of the chromosomes for the evaluated
genes.
When we compared the occurrence of genotypes in se-
verely and moderately affected dogs, most of the genotypes
actually were present in both groups (Table 4). When looking
at specific haplotype frequencies in severe versus moderately
affected dogs, we observed no significant differences in the
major haplotypes for RPGRIP1, NPM1, NPHP5, ABCA4, and
PDE6D. Frequencies between the two phenotypes were simi-
lar in the case of RPGRIP1, NPM1, and NPHP5 major
haplotypes, and not discrepant enough in ABCA4 and PDE6D
to account for the level of affection. By contrast, a discrep-
ancy was observed in the RANBP2 haplotype 1 frequency be-
tween severely and moderately affected dogs (43% versus
11%). This haplotype was present in 11 out of 14 severely
affected dogs (heterozygous in 10, and homozygous in 1), but
only in two out of nine moderately affected dogs. In addition,
15 haplotypes were considered as minor in the affected dogs,
i.e. accounting for five chromosomes or fewer out of the 46
chromosomes for the gene considered.
Gene expression:  Expression studies were done on total
retinal RNA from eight affected and three nonaffected dogs to
examine the relative expression level of the candidate genes.
This was determined by amplifying cDNA-specific markers
and reporting PCR products relative to the ALDOA control.
By this method, only the quantitative aspect of transcript lev-
els were estimated, but no conclusions can be made at this
time about changes that may occur at the protein level. The
TABLE 4. GENOTYPES OF THE SIX GENES OF INTEREST IN SEVERELY AND
MODERATELY AFFECTED DOGS
       RPGRIP1   RANBP2   NPM1   PDE6D   NPHP5   ABCA4
----   -------   ------   ----   -----   -----   -----
Severely affected
H2     2,2       1,2      1,1    1,4     1,1     1,2
H64    2,5       2,1      1,2    4,4     1,2     1,2
H104   1,1       3,2      2,1    5,4     2,1     4,1
H105   1,1       3,1      2,1    5,2     3,1     4,1
H78    3,1       3,1      1,1    1,1     1,1     1,1
H79    3,1       3,1      1,1    1,2     2,1     1,1
H82    1,2       2,1      1,1    1,2     1,1     3,1
H143   4,1       7,1      6,1    1,1     4,1     2,3
H35    3,5       5,1      4,2    2,4     2,1     5,2
H38    4,2       3,1      1,2    2,3     2,2     3,2
H71    4,2       3,2      1,1    2,2     2,1     3,1
H72    2,1       2,1      2,1    3,4     2,1     3,1
H73    2,2       1,1      2,1    3,2     2,1     3,1
H118   1,4       5,2      5,1    5,2     4,2     1,3
Moderately affected
H29    3,1       2,3      1,1    1,2     2,1     3,1
H31    3,2       5,6      1,1    1,2     2,3     5,1
H130   1,2       3,4      1,1    3,3     3,1     4,2
H131   4,5       3,4      1,2    5,3     3,1     1,2
H81    3,2       3,2      1,1    1,2     2,1     1,1
H208   1,1       4,2      3,1    1,2     2,1     1,2
H59    3,1       2,1      1,3    1,2     1,1     3,2
H201   2,2       6,1      3,1    1,4     2,1     2,2
H202   1,2       3,4      1,2    1,3     2,1     2,2
Alleles are numbered from one to seven according to haplotypes
shown in Table 3. Genotypes that are present in both severe and
moderate phenotypes are in red color.
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results were highly reproducible as evidenced by the relative
standard deviation (SD/AV) calculated from the three inde-
pendent repeats. In most cases, this ratio did not exceed 10%
for a given gene in a given retina. Relative expression as a
function of age in affected and nonaffected dogs for the six
genes of interest is presented on Figure 3.
To assess the retinal integrity, we first examined opsin
expression to establish the integrity of the retinal samples, and
found no differences between control and mutant retinas.
RANBP2, NPM1, PDE6D, and ABCA4 showed a rather con-
stant expression in affected retinas, and the expression did not
exceed a 1.5 fold difference in relative units from 6 to 67 weeks
©2007 Molecular VisionMolecular Vision 2007; 13:1094-105 <http://www.molvis.org/molvis/v13/a119/>
Figure 2. Haplotype frequencies in RPGRIP1, RANBP2, NPM1, PDE6D, NPHP5, and ABCA4 in normal dogs, and affected dogs with severe
and moderate phenotypes.  Haplotypes were numbered from one to seven, and frequencies were calculated from subsets of 10 normal, 9
moderate, and 14 severe XLPRA1 dogs. Table 3 identifies the haplotypes tested for each of the genes.
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of age. Control retinas showed slight variations for the period
considered. Therefore age or status does not have any notable
effect on these genes for the time period analyzed. In contrast,
NPHP5 expression varied by a more than twofold difference
in relative units from 6 to 67 weeks of age while the control
retinas showed a steady expression. Similarly, RPGRIP1 ex-
pression varied by a threefold difference in relative units. In
this case, however, the control retinas also showed some fluc-
tuations for the time period examined. These variations are
obviously not related to the age, and their relationship with
the affected status is unknown at this time. As the expression
in the affected retinas showed a similar pattern that differed
primarily in magnitude for some of the genes, it is likely that
these differences reflect specific sample differences rather than
a disease-specific change.
DISCUSSION
 The canine XLPRA1 model of RPGR-XLRP is a naturally
occurring microdeletion that results in a stop mutation in exon
ORF15, the mutation hotspot for RPGR in humans [13]. In
the study population, the disease originated from a single
mutant X-chromosome, yet affected animals showed great
©2007 Molecular VisionMolecular Vision 2007; 13:1094-105 <http://www.molvis.org/molvis/v13/a119/>
Figure 3. Relative expression levels of RPGRIP1, RANBP2, NPM1, PDE6D, NPHP5, and ABCA4 genes in pre-degenerate XLPRA1 affected
retinas.  Expression level of opsin (RHO) is also shown as a control of retinal integrity. Normal retinas are in black symbols and lines; affected
retinas are in light gray symbols and lines. Standard deviations calculated from 3 repeats also are shown.
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phenotypic variability in severity. As the disease represents a
stable mutation with no heterogeneity at the primary locus
(RPGR), the XLPRA1 pedigree is a suitable resource to ex-
amine genetic modifiers on the phenotypic variability of dis-
ease. Such studies would have direct relevance to human
XLRP.
However the search for such genetic modifiers of pheno-
type by classical association methods is difficult due to the
very characteristics of that trait of interest, and limitations in
the study population. Because the severity status is accessible
only in affected animals, matings with normal or carrier dogs
are not fully informative on the transmission of the pheno-
type, preventing a classical linkage analysis. Linkage disequi-
librium (LD) analysis would provide an alternative approach
to identifying shared haplotypes correlated with a phenotype.
This was successfully carried out in dogs recently, and en-
abled an ancestral disease transmitting chromosome with a
novel retinal degeneration gene to be identified [38,40]. This
approach would require multiple independently ascertained
affected individuals that are not closely related. However,
XLPRA1 does not exist outside the specific research colony
as commercial testing over a 3-4 year period has not identi-
fied any affected individuals or mutant chromosomes in the
population (Dr. Jeanette Felix, OptiGen LLC, personal com-
munication). Thus the relatively small and inbred affected
population from our pedigree is not suitable for analysis using
LD.
Because of these limitations, we directed our analysis to
identifying candidate gene-specific haplotypes, and their fre-
quencies were compared in severely versus moderately affected
dogs to determine if there were a putative correlation between
haplotype and phenotype. Such an approach is now possible
given the recent wealth of canine genomic resources, e.g. 1.5x
TIGR sequence [41], 7.6x public sequence [42], and a robust
SNP resource (Broad). In this study we investigated six can-
didate modifier genes. RPGRIP, RANBP2, NPM1, PDE6D,
and NPHP5 were selected on the basis of protein interaction
with RPGR or RPGRIP1 as these two proteins independently
cause photoreceptor degeneration when mutated; ABCA4 was
selected as a control gene, and because of its association with
macular degeneration and RP [36,37].
By carrying out this strategy, some of the characteristics
of the XLPRA1 pedigree were revealed. The random sequenc-
ing of 16.3 kb of non-coding regions around RPGRIP1,
RANBP2, and NPM1 genes gave us an estimated SNP discov-
ery rate of 1/850 bp. Even though the outcrossed pedigree rep-
resents founders from multiple breeds, e.g. beagle, elkhound,
and Irish setter in addition to Siberian husky [15], which would
have been expected to contribute genotypic diversity and
breed-specific polymorphisms, this figure is in close agree-
ment to the 1/1000 bp reported for the dog genome [42]. More-
over, the Siberian husky, like the Alaskan malamute, belong
to the Asian breed cluster [43], and is expected to diverge even
more from the other contributing breeds. Therefore the poly-
morphism in our pedigree is mainly of inter-breed origin as a
small number of founder in each breed were used.
The number of haplotypes finally identified is clearly re-
lated to the number of polymorphic sites used to define them.
Although we identified additional polymorphisms, these
brought redundant information, and are not included in the
analysis. Because of the structure of our pedigree, we esti-
mated that a maximum of 13 of the 20 chromosomes brought
by the 10 founders could have contributed to the affected dogs.
However, only four to seven haplotypes were identified in each
of the candidate modifier genes analyzed. This discrepancy
arises, in part, by the high inbreeding of the pedigree, and is
also a function of the gene locus analyzed. In most dog breeds,
the genome features regions of near-total homozygosity alter-
nating with regions of high heterozygosity, implying that the
genome is comprised of large blocks with limited diversity
[42,44]. Thereby the haplotype diversity of a given region in
our pedigree depends on the heterozygosity of that region
within and between the contributing breeds.
We found that moderately and severely affected dogs had
no major discrepancies in haplotype frequencies for RPGRIP1,
NPM1, PDE6D, NPHP5, and ABCA4, which suggests these
genes are not modifiers of disease phenotype. In contrast, we
found an overrepresentation of RANBP2 haplotype 1 in the
severe disease class, with 11 of the 14 dogs in the group hav-
ing this haplotype in one [10] or both [1] chromosomes. This
distribution would indicate that the RANBP2 haplotype 1 be-
haves as a susceptibility allele for the disease. On closer ex-
amination, however, if we exclude the dog H2, the severely
affected group consists of nine dogs with only one parent het-
erozygous for the haplotype 1 i.e. 50% chance to inherit this
allele, and four dogs with both parents heterozygous, i.e. 75%
chance to inherit at least one copy of haplotype 1. The moder-
ately affected group consists of seven dogs with only one par-
ent heterozygous for the haplotype 1, i.e. 50% chance to in-
herit the haplotype 1 and two dogs with no parents with this
haplotype. Therefore the observed ratio of 10 severely affected
dogs with the haplotype 1 versus two moderately affected dogs
is not significantly different from what was expected (7.5 ver-
sus 3.5), and an association between RANBP2 and disease se-
verity can not be made.
In a complementary study, we analyzed the relative ex-
pression of the candidate modifier genes in normal and pre-
degenerate XLPRA1 retinas in relation to an internal control
gene [39]. Because severity status could not be determined a
priori in the samples used for the expression studies, we se-
lected ages prior to photoreceptor degeneration, and used op-
sin expression as an independent measure of retinal integrity.
Both the normal and mutant samples showed the same levels
of opsin expression, thus establishing that the photoreceptors
were not degenerate. Furthermore, we reasoned that if there
were differential expression of the candidate genes between
severely and moderately affected retinas, a difference between
normal and affected retina should be identified first. In the
case of RANBP2, NPM1, PDE6D, and ABCA4, the relative
expression levels of affected and non-affected retinas were
comparable for the time period analyzed. The slight decrease
in expression level of affected retinas between 20 and 50 weeks
©2007 Molecular VisionMolecular Vision 2007; 13:1094-105 <http://www.molvis.org/molvis/v13/a119/>
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may reflect that this large time interval contains only a single
sample that may not be representative. Other than that, most
of variations between normal and affected retinas did not ex-
ceed a twofold difference, which was considered not large
enough to be of significance. For RPGRIP1 and NPHP5, how-
ever, a lower expression was observed in 48 (RPGRIP1,
NPHP5), and 67 (RPGRIP1) week old affected retinas that
could reflect initial stages of the disease process, prior to the
onset of degeneration. However, these values are similar to
those obtained from the control retinas. This will require ex-
amination of additional samples at different time points using
more quantitative approaches, and would be facilitated by
having homogeneous lines of dogs that predictably have mod-
erate or severe disease.
In this study, we used a semi quantitative method to ex-
amine variations in mRNA expression levels between normal
and affected retinas. Qualitative variations at the sequence level
in the candidate genes may also exist between normal and
affected retinas. As well, variations at the protein level could
exist, and possibly be responsible for the observed phenotype
variations. Additional studies would be required to address
these issues.
In addition to the genes analyzed, other genes have been
identified recently that interact with RPGR or RPGRIP, and
warrant further examination. With expansion of the pedigree
resources currently in progress, these genes will be examined
in a subsequent screen. NPHP4 codes for an RPGRIP-inter-
acting protein [45], and NPHP6 for an RPGR associated pro-
tein [46]; both are good candidate modifier genes as, when
mutated, they result in retinal degeneration. In addition, SMC1
and SMC3 have been shown to interact directly with RPGR
via its RCC1 domain, while IFT88 and kinesin-2 proteins have
been shown to be part of the RPGR complex [47]. Candidate
modifier genes also could be selected following other criteria,
but one of the most promising ways to identify the genes is to
investigate the genome in its entirety. Such studies have al-
ready been performed in mice by mating strains showing vari-
able loss of photoreceptors in age-related retinal degeneration
[48], or after prolonged light exposure [49]. This led to the
identification of quantitative trait loci (QTLs) with protective
alleles in both cases. The resources needed to do this work in
dogs are not available at present, or in the foreseeable future.
However, once candidate genes are identified they can be
readily tested in association studies using the available pedi-
gree resources.
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